血清中趋化素在非小细胞肺癌中的表达和预后意义

摘要

目的 探讨非小细胞肺癌(NSCLC)血清中趋化素的表达和临床意义.方法 收集120例非小细胞肺癌和86例健康人血清样本,通过酶联免疫ELISA试剂盒检测血清中趋化素表达量,分析其与非小细胞肺癌的临床病理特征关系以及诊断价值和预后关系.结果 血清中趋化素在NSCLC患血清中的表达显著高于健康人正常血清中的表达量(t=6.68,P<0.01);非小细胞肺癌患者血清中趋化素高表达与淋巴结转移、远端转移、疾病分期、吸烟史均具有显著相关性(t=4.783,P=0.0025<0.01;t=5.261,P=0.0013<0.01;t=4.527,P=0.0035 <0.01;t =5.216,P =0.0023 <0.01);ROC 曲线分析 AUC =0.8813(95% CI,0.7324 -0.8979;P<0.001);灵敏性和特异性分别是60.7%和88.4%;血清中趋化素低表达和高表达组在中位总生存时间 OS上的差异具有统计学意义(χ2=8.408,P=0.0037<0.01).结论 血清中趋化素在非小细胞肺癌中是高表达的,可以作为非小细胞肺癌的新型生物标记物和诊断靶标.%Objective To investigate the expression and clinical significance of serum chemerin in non-small cell lung cancer(NSCLC). Methods Serum specimens from 120 NSCLC patients and 86 healthy controls were col-lected. The levels of serum chemerin were measured by sandwich enzymelinked immunosorbent assay(ELISA). The association between the clinic-pathological characteristics,prognosis and diagnostic value and serum chemerin of pa-tients were further investigated. Results The level of serum chemerin was significantly higher in the NSCLC group than in the healthy controls (t=6.68, P<0.01). The higher level of serum chemerin was significantly associated with advanced lymph node metastasis,distant metastasis,TNM stage,and smoking history (t=4.783, P=0.0025<0.01;t=5.261,P=0.0013<0.01;t=4.527,P=0.0035<0.01;t=5.216, P=0.0023<0.01). The area under the ROC curve was 0.8813 (95% CI,0.7324-0.8979;P<0.001),and the sensitivity and specificity was 60.7% and 88.4%. The low serum chemerin expression and high serum chemerin expression groups were statistical-ly significant in overall survival time(x2=8.408,P=0.0037<0.01). Conclusion The measurement of chemerin may be a useful diagnostic and prognostic biomarker for NSCLC patients.